CERENOME, INC.
Plus Therapeutics, Inc. (Nasdaq Capital Market: PSTV) is a U.S. healthcare company headquartered in Houston, Texas, developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system cancers. The company operates through two primary business segments: radiopharmaceuticals… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What CERENOME, INC. does
In the company’s own words
Plus Therapeutics, Inc. (Nasdaq Capital Market: PSTV) is a U.S. healthcare company headquartered in Houston, Texas, developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system cancers. The company operates through two primary business segments: radiopharmaceuticals and diagnostic testing.
In radiopharmaceuticals, Plus Therapeutics' lead candidate is rhenium-186 obisbemeda, a patented radiotherapy designed for direct localized delivery to CNS cancers including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers using convection-enhanced delivery and intraventricular catheters. The company is also developing Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere technology for treating solid organ cancers through intra-arterial injection. These novel formulations encapsulate radionuclides with nanoliposomes and microspheres to deliver targeted radiation doses while minimizing exposure to healthy tissue.
The diagnostic segment operates through CNSide Diagnostics, LLC, a wholly owned subsidiary that develops and commercializes laboratory-developed tests for identifying tumor cells that have metastasized to the central nervous system. The CNSide platform consists of four laboratory-developed tests utilizing tumor cell enumeration, immunocytochemistry, fluorescence in situ hybridization, and next-generation sequencing. The company re-introduced the CNSide Test in August 2025 and has established a CLIA-accredited laboratory in Houston, Texas. CNSide Diagnostics has signed national agreements with UnitedHealthcare Insurance Company and Humana, Inc., expanding access to more than 67 million covered lives.
Plus Therapeutics' radiopharmaceutical development is supported by significant government funding, including a $3.0 million National Institutes of Health/National Cancer Institute award for rhenium-186 obisbemeda development for recurrent glioblastoma, a $17.6 million Cancer Prevention and Research Institute of Texas grant for leptomeningeal metastases research, and a $3.0 million Department of Defense award for pediatric brain cancer research. The company licenses its core technologies from academic institutions and operates through multiple clinical trials including the ReSPECT-GBM, ReSPECT-LM, and ReSPECT-PBC studies. The company's intellectual property portfolio includes multiple patent families covering its nanoliposome formulations, manufacturing methods, and diagnostic platform technologies with expiration dates extending through 2043.
Company details
- Sector
- Healthcare
- Industry
- Surgical & Medical Instruments
- Headquarters
- HOUSTON, TX
- Fiscal year end
- December
- CIK
- 1095981
- SIC
- 3841
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns CERENOME, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · CERENOME, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do CERENOME, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of CERENOME, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in CERENOME, INC.'s last four quarterly filings that the numbers alone won't show?”